ArticleJournal of cancer research and clinical oncology2023

A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma.

Pengcheng He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.